NexJen Bio: Next-Generation Clinical Platform

Executive Summary

NexJen Bio is a pioneering biotechnology company revolutionizing investment decisions in pharma and biotech. Our physics-informed AI provides unmatched accuracy in:

• Predicting clinical outcomes
• Ranking business development (BD) opportunities
• Forecasting IPO timing

We leverage Multimodal Data Fusion, Mechanistic Modeling, and Competitive Intelligence to address the critical need for data-driven decision-making in a high-stakes industry.

---

Market Opportunity

• Cost: Average drug development = ≈\$2.6B
• Success rate: <10%

• Problems today:

  • Inaccurate forecasting
  • Data overload
  • Fragmented tools
  • Information asymmetry

Our solution: A unified, AI-powered platform that transforms disparate data into actionable insights.

---

Product Overview

1. Web — Insight Hub A holistic dashboard of clinical + financial data (PoS, enrollment risk, red flags, competitive density heatmaps).

2. API — Risk Scoring Endpoints JSON-formatted PoS scores with evidence, embeddable into CRO/LIMS or portfolio dashboards.

3. Mobile — Paper & Signal Feed An “ArXiv-meets-ClinicalTrials” app with personalized alerts for executives.

Core features:

• Clinical trial dashboard
• Literature synthesizer (RAG pipeline: PubMed + bioRxiv)
• Trial tracker (phase-transition curves, enrollment forecasts)
• BD & IPO scoring module

---

Technology & Implementation

Models

• GBDT PoS estimator: trained on >35,000 transitions
• GNN: maps target–disease–MOA relationships
• Ensemble survival + transformer
• IPO forecaster: stacked LSTMs + XGBoost on >1,000 IPOs

Math (sketch)

• Survival probability (at horizon $t^{\ast}$):

$$ S(t) = \exp!\left(-\int_0^t h(u)\,du\right), \qquad \hat{p}_{\text{advance}} = 1 - S(t^{\ast}). $$

• Ensemble for PoS:

$$ \hat{y} = \alpha\,\hat{y}_{\mathrm{GBDT}}

• \beta\,\hat{y}_{\mathrm{Survival}}
• \gamma\,\hat{y}_{\mathrm{Transformer}}, \qquad \alpha + \beta + \gamma = 1. $$

Data Infrastructure

• Multimodal fusion (ClinicalTrials.gov, EudraCT, PubMed, SEC filings, market data)
• Cloud-native, scalable architecture

---

Business Model

• Insight Hub (Web):

  • Pro: \$499/user/month
  • Enterprise: custom pricing (incl. API + on-prem)

• Risk Scoring API: pay-per-call or tiered subscription

• Mobile app: freemium; premium bundled with Hub

---

Go-to-Market Strategy

• Content marketing: white papers, case studies
• Digital: SEO/SEM + targeted social
• Direct sales: pharma, biotech, VCs
• Partnerships: CROs, LIMS vendors

---

Team

• CEO (founder): Nicole Guo — BS UNC Chapel Hill, MS Bioinformatics, Columbia
• CTO (co-founder): Joy Bu — BS UCSD, PhD Neuroscience, UCB
• CFO (co-founder): Kiara Casmer, BS UNC Chapel Hill, Goldman Sachs IBD Healthcare Classic
• Advisory Board: professors, pharma, biotech, VC leaders

---

Risk Mitigation

• Market adoption: freemium, pilots, ROI case studies
• Competition: continuous innovation, BD/IPO differentiation
• Technical: strong MLOps, validation
• Regulation: GDPR/HIPAA-compliant workflows

Built With

• python